CING (Cingulate) Buyback Yield %: -45.31 (As of Jun. 29, 2026)


CING Cingulate Inc CING
33 GF Score
Price $4.94
! 1 Warning Sign
View Full Analysis

What is Cingulate Buyback Yield %?

Cingulate CING +4.20% 33 Buyback Yield % is -45.31 as of Jun. 29, 2026. GuruFocus rates CING with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Cingulate ranks worse than 81.81% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cingulate's current buyback yield was -45.31%.

Cingulate Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Cingulate's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Buyback Yield % Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -65.44 0.00 -78.29 -154.28 -32.27

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.81 -105.53 -38.65 -32.27 -40.77

CING vs IMA, MCRB, PLRX: Buyback Yield % Comparison

For the Biotechnology subindustry, Cingulate's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cingulate's Buyback Yield % falls into.


CING
33GF Score
Cingulate Inc CING
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cingulate Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cingulate's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10.154) / 31.465
=-32.27%

Cingulate's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 30.147) / 73.94868
=-40.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -45.31 mean?
Cingulate (CING) has a Buyback Yield % of -45.31 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cingulate and its competitors. According to the industry distribution chart, Cingulate ranks #607 out of 742 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Cingulate's Buyback Yield % too high?
Cingulate's current Buyback Yield % is -45.31. Based on the distribution chart, Cingulate ranks #607 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cingulate has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Buyback Yield % compare to IMA and MCRB?
According to the Biotechnology industry distribution chart, Cingulate ranks #607 out of 742 companies for Buyback Yield %. This places Cingulate in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cingulate and its competitors. Cingulate's current Buyback Yield % is -45.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Buyback Yield % of -45.31. The current Buyback Yield % is -45.31. Cingulate's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cingulate (CING), the current Buyback Yield % is -45.31 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
33GF Score

Get the complete analysis for CING

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.94
Price